Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease

Journal of Human Hypertension

Volumn 17, Issue 4, 2003, Pages 271-276

  Matsuda, H ^a,b   Hayashi, K ^a   Saruta, T ^a  

^a KEIO UNIVERSITY   (Japan)

^b ASHIKAGA RED CROSS HOSPITAL   (Japan)

Author keywords

Angiotensin receptor antagonists; Angiotensin converting enzyme; Nitric oxide; Proteinuria; Renal protection

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ; CANDESARTAN HEXETIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; NITRATE; NITRIC OXIDE; NITRITE; PERINDOPRIL; PROTEIN; TRANDOLAPRIL;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROTECTION; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TIME SERIES ANALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHRONIC DISEASE; CREATININE; DIASTOLE; FEMALE; HUMANS; JAPAN; KIDNEY DISEASES; MALE; MIDDLE AGED; NITRIC OXIDE; POTASSIUM; PROTEINURIA; RANDOM ALLOCATION; RECEPTORS, ANGIOTENSIN; SEVERITY OF ILLNESS INDEX; SYSTOLE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0038736940     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001543     Document Type: Article

References (23)

1. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Chin Invest 1986; 77: 1993-2000.
2. Taguma Y et al. Effect of captopril on heavy proteinuria in azometic diabetics. N Engl J Med 1985; 313: 1617-1620.
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 326: 1456-1462.
4. Maschio G et al. AIPRI Study Group. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945.
5. Brenner BM et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
6. Lewis EJ et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
7. Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44: 545-550.
8. Matsuda H et al. Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: Role of intrarenal bradykinin. J Am Soc Nephrol 1999; 10: 2272-2282.
9. Gainer JV et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285-1292.
10. Siragy HM, Jaffa AA, Margolius HS, Carey RM: Renin-angiotensin system modulates renal bradykinin production. Am J Physiol 1996; 271: R1090-R1095.
11. Nishimoto M et al. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation. Circulation 2001; 104: 1274-1279.
12. Russo D et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18-25.
13. Tokuyama H et al. Role of intrarenal angiotensin II (AII) and cyclooxygenase (COX)-1/2 in chronic ischemic nephropathy. J Hypertens 2000; 18 (Suppl 4): S12.
14. Ohta K et al. A novel in vivo assay system for consecutive measurement of brain nitric oxide production combined with the microdialysis technique. Neurosci Lett 1994; 176: 165-168.
15. Liu Y-H et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99: 1926-1935.
16. Carey RM, Jin X, Wang Z, Siragy HM. Nitric oxide: A physiological mediator of the type 2 (AT2) angiotensin receptor. Acta Physiol Scand 2000; 168: 65-71.
17. Adler L et al. Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: Effect on urinary albumin, TGF-B, and nitrite excretion. BMC Nephrol 2002; 3: 2.
18. Rahma M et al. Effects of furosemide on the tubular reabsorption of nitrates in anesthetized dogs. Eur J Pharmacol 2001; 428: 113-119.
19. Sosa-Canache B, Cierco M, Gutierrez CI, Israel A. Role of bradykinin and nitric oxide in the AT2 receptor-mediated hypotension. J Hum Hypertens 2000; 14: 4S40-S46.
20. Siragy HM, De Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000; 35: 1074-1077.
21. Weir MR, Henrich WL. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens 2000; 9: 403-411.
22. Ehara T, Shigematsu H. Contribution of mast cells to the tubulointerstitial lesions in IgA nephritis. Kidney Int 1998; 54: 1675-1683.
23. Ghiadoni L et al. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35 (1 Part 2): 501-506.